Key result
NDC-1171 preserves LVEF by ~7% vs vehicle in DMD mice without improving skeletal muscle function.
Why the study?
Progressive cardiomyopathy is the leading cause of death in Duchenne muscular dystrophy, with dysregulation of calcium handling implicated in its progression.
Does the SERCA pump modulator NDC-1171 attenuate cardiac functional decline in a mouse model of Duchenne muscular dystrophy?
Does the SERCA pump modulator NDC-1171 attenuate cardiac functional decline in a mouse model of Duchenne muscular dystrophy?
The novel SERCA pump positive allosteric modulator NDC-1171 significantly preserved left ventricular ejection fraction in a mouse model of Duchenne muscular dystrophy, highlighting a potential therapeutic approach for DMD-associated cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Does not support clinical use; leaves open SERCA modulation for DMD cardiomyopathy in future studies.
Progressive cardiomyopathy is the leading cause of death in Duchenne muscular dystrophy (DMD). Dysregulation of calcium handling has been implicated in cardiomyopathy progression in DMD. Here we describe a therapeutic approach to improve calcium homeostasis in a mouse model of DMD using the novel therapeutic NDC-1171, which is a positive allosteric modulator of the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) pump. We synthesized NDC-1171 and treated 4-week-old D2. mdx mice (n=9) via oral gavage. A group of D2. mdx mice (n=9) and a group of DBA/2J mice (n=9; background strain) received a vehicle on the same schedule. We used ultrasound to assess left ventricular function, followed by a treadmill exhaustion test and a 4-paw grip strength test to assess skeletal muscle function. NDC-1171 attenuated cardiac functional decline in D2. mdx mice. At 16 weeks of age, left ventricular ejection fraction (LVEF) was significantly preserved in mice treated with NDC-1171 (57.7□±□0.5%) compared to mice treated with a vehicle (50.7□±□0.9%, p □<□0.05), though remained lower than background strain controls (62.4□±□0.6%). In contrast, functional behavior testing revealed no significant improvement in skeletal muscle function with treatment. These data suggest that treatment with the SERCA pump modulator NDC-1171 helps preserve cardiac function in a murine model of DMD, even as skeletal muscle function was impaired. Future work will be needed to determine if the benefits of this novel SERCA activator translate to large animal and clinical studies, but these initial results are promising and could help guide development of future treatments for pediatric patients with muscular dystrophy.
No takes yet. Share an insight, caveat, or question.
Narra et al. (2026) studied Duchenne muscular dystrophy (murine model) (n=27). NDC-1171 vs. Vehicle was evaluated on Left ventricular ejection fraction (LVEF) at 16 weeks (p=<0.05). NDC-1171 preserved left ventricular ejection fraction compared to vehicle in a mouse model of Duchenne muscular dystrophy, though skeletal muscle function did not improve.
Synapse has enriched 10 related papers. Consider them for comparative context: